Protalix BioTherapeutics Inc (PLX) Options Open Interest

Monitoring PLX open interest helps you see where real money is positioned on Protalix BioTherapeutics Inc's options and which strikes are attracting the most commitment from traders. Protalix BioTherapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor PLX options open interest in real time and find the strikes that matter.

Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising PLX options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Protalix BioTherapeutics Inc to settle.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases.

The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where PLX open interest is concentrated. Our scanner maps Protalix BioTherapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Protalix BioTherapeutics Inc's options open interest as the signal it is, not as an afterthought.